XML 71 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1

Collaboration Agreements And Business Development Activities - Royalty Pharma (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2022	Jan. 03, 2025	Dec. 29, 2023	Dec. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration agreement percent of royalty on net sale		3.00%
Collaborative Arrangements with Glaxo Smith Kline
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration agreement percent of royalty on net sale	3.00%
Collaborative Arrangements with Royalty Pharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty expense		$ 75.5	$ 68.0	$ 58.2

X

- Definition

Collaboration Agreement, Percent Of Royalty On Net Sale

+ References

No definition available.

+ Details

Name:	exel_CollaborationAgreementPercentOfRoyaltyOnNetSale
Namespace Prefix:	exel_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementsWithRoyaltyPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: